Literature DB >> 30311843

Evidence of unrestrained beta-cell proliferation and neogenesis in a patient with hyperinsulinemic hypoglycemia after gastric bypass surgery.

Nidheesh Dadheech1, Dominique Garrel2, Jean Buteau1.   

Abstract

Hyperinsulinemic hypoglycemia syndrome (HIHG) is a rare complication of roux-en-Y gastric bypass surgery. The pathology is associated with an excessive function of pancreatic beta-cells, and requires pancreas resection in patients that are recalcitrant to nutritional and pharmacological interventions. The exact prevalence is not clearly understood and the underlying mechanisms not yet fully characterized. We herein sought to perform histological and molecular examination of pancreatic sections obtained from a patient who developed HIHG as a complication of gastric bypass compared to 3 weight-matched controls. We studied markers of cellular replication and beta-cell differentiation by immunohistochemistry and immunofluorescence. HIHG after gastric bypass was characterized by a profound increase in beta-cell mass. Cellular proliferation was increased in islets and ducts compared to controls, suggesting unrestrained proliferation in HIHG. We also detected beta-cell differentiation markers in duct cells and occasional duct cells displaying both insulin and glucagon immunoreactivity. These histological observations suggest that beta-cell differentiation from ductal progenitor cells could also underly beta-cell mass expansion in HIHG. Altogether, our results can be construed to demonstrate that HIHG after gastric bypass is characterized by abnormal beta-cell mass expansion, resulting from both unrestrained beta-cell replication and neogenesis.

Entities:  

Keywords:  HIHG; bariatric surgery; beta-cell; gastric bypass; neogenesis; nesidioblastosis; panIN; proliferation

Mesh:

Year:  2018        PMID: 30311843      PMCID: PMC6300081          DOI: 10.1080/19382014.2018.1513748

Source DB:  PubMed          Journal:  Islets        ISSN: 1938-2014            Impact factor:   2.694


  22 in total

1.  Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.

Authors:  Lars Sjöström; Anna-Karin Lindroos; Markku Peltonen; Jarl Torgerson; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Bo Larsson; Kristina Narbro; Carl David Sjöström; Marianne Sullivan; Hans Wedel
Journal:  N Engl J Med       Date:  2004-12-23       Impact factor: 91.245

Review 2.  ASMBS Position Statement on Postprandial Hyperinsulinemic Hypoglycemia after Bariatric Surgery.

Authors:  Dan Eisenberg; Dan E Azagury; Saber Ghiassi; Brandon T Grover; Julie J Kim
Journal:  Surg Obes Relat Dis       Date:  2016-12-19       Impact factor: 4.734

Review 3.  Advances in the etiology and management of hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass.

Authors:  Yunfeng Cui; Dariush Elahi; Dana K Andersen
Journal:  J Gastrointest Surg       Date:  2011-06-14       Impact factor: 3.452

4.  Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased beta-cell turnover.

Authors:  Juris J Meier; Alexandra E Butler; Ryan Galasso; Peter C Butler
Journal:  Diabetes Care       Date:  2006-07       Impact factor: 19.112

5.  Hypoglycemia after Roux-en-Y gastric bypass: the BOLD experience.

Authors:  Hafiz Sarwar; William H Chapman; John R Pender; Andrada Ivanescu; Almond J Drake; Walter J Pories; Moahad S Dar
Journal:  Obes Surg       Date:  2014-07       Impact factor: 4.129

Review 6.  Behavioral treatment of obesity.

Authors:  Meghan L Butryn; Victoria Webb; Thomas A Wadden
Journal:  Psychiatr Clin North Am       Date:  2011-12

7.  Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery.

Authors:  Geoffrey J Service; Geoffrey B Thompson; F John Service; James C Andrews; Maria L Collazo-Clavell; Ricardo V Lloyd
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

Review 8.  Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery.

Authors:  Joshua P Thaler; David E Cummings
Journal:  Endocrinology       Date:  2009-04-16       Impact factor: 4.736

Review 9.  An evolving scientific basis for the prevention and treatment of pediatric obesity.

Authors:  P T Katzmarzyk; S Barlow; C Bouchard; P M Catalano; D S Hsia; T H Inge; C Lovelady; H Raynor; L M Redman; A E Staiano; D Spruijt-Metz; M E Symonds; M Vickers; D Wilfley; J A Yanovski
Journal:  Int J Obes (Lond)       Date:  2014-03-25       Impact factor: 5.095

10.  Mechanism of metabolic advantages after bariatric surgery: it's all gastrointestinal factors versus it's all food restriction.

Authors:  Filip K Knop; Roy Taylor
Journal:  Diabetes Care       Date:  2013-08       Impact factor: 19.112

View more
  4 in total

Review 1.  Impact of bariatric surgery on type 2 diabetes: contribution of inflammation and gut microbiome?

Authors:  Jean Debédat; Chloé Amouyal; Judith Aron-Wisnewsky; Karine Clément
Journal:  Semin Immunopathol       Date:  2019-04-25       Impact factor: 9.623

2.  Repurposed Analog of GLP-1 Ameliorates Hyperglycemia in Type 1 Diabetic Mice Through Pancreatic Cell Reprogramming.

Authors:  Adrian Villalba; Silvia Rodriguez-Fernandez; David Perna-Barrull; Rosa-Maria Ampudia; Laia Gomez-Muñoz; Irma Pujol-Autonell; Eva Aguilera; Mireia Coma; Mary Cano-Sarabia; Federico Vázquez; Joan Verdaguer; Marta Vives-Pi
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-13       Impact factor: 5.555

3.  Brunner's Gland Hyperplasia in a Patient after Roux-Y Gastric Bypass: An Important Pitfall in GLP-1 Receptor Imaging.

Authors:  Matthias Hepprich; Kwadwo Antwi; Beatrice Waser; Jean Claude Reubi; Damian Wild; Emanuel R Christ
Journal:  Case Rep Endocrinol       Date:  2020-04-03

4.  Differential effects of RYGB surgery and best medical treatment for obesity-diabetes on intestinal and islet adaptations in obese-diabetic ZDSD rats.

Authors:  Ananyaa Sridhar; Dawood Khan; Mahmoud Abdelaal; Jessie A Elliott; Violetta Naughton; Peter R Flatt; Carel W Le Roux; Neil G Docherty; Charlotte R Moffett
Journal:  PLoS One       Date:  2022-09-22       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.